Topic
Semaglutide, tirzepatide, retatrutide and the rest of the incretin family, plus the older metabolic and diabetes compounds people run alongside or instead of them.
Almost everything here is dosed on a ladder rather than at a fixed amount, which is what makes it worth tracking properly: the dose changes on a schedule, a missed week has consequences for the next step, and the side effects that decide whether you hold or climb show up days after the injection that caused them. Weight is the obvious number and the least useful one on its own — what separates a plateau from a stall is what is happening to lean mass underneath it.
No. Every range here describes what is reported in the literature or commonly tracked. Where an approved product exists its FDA label is linked on the compound page, and that label — not this site — is the authority on dosing.
Waist, and body composition if you have access to a scale or a scan. A stall with lean mass holding steady and a stall with lean mass falling are different problems. Side effects paired to the day you dosed are the other half, because that pairing is what tells you whether a step up was tolerated.
The GLP-1 titration planner maps semaglutide, tirzepatide and liraglutide ladders onto real dates and shows the week you reach maintenance.
Every figure on these pages is sourced the same way — see the editorial policy for the hierarchy, and the full library for all 208 compounds.